What is it about?
We investigated the effects of probenecid, an OAT3 inhibitor, on the pharmacokinetics and safety of ritobegron, a selective b3-adrenoceptor agonist, in humans. Probenecid increased the AUC0–48 h of KUC-7322, an active form of ritobegron, by 3 times and decreased the renal clearance by 1/4. On the other hand, probenecid did not influence adverse events of ritobegron.
Featured Image
Read the Original
This page is a summary of: Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3-Adrenoceptor Agonist, With Probenecid in Healthy Men, Clinical Pharmacology in Drug Development, September 2015, Wiley,
DOI: 10.1002/cpdd.212.
You can read the full text:
Contributors
The following have contributed to this page
